Topoisomerase I inhibition with topotecan: pharmacologic and clinical issues

Expert Opinion on Pharmacotherapy
B Arun, E P Frenkel

Abstract

Topoisomerase I (topo-I) inhibitors are a new class of anticancer agents with a mechanism of action aimed at interrupting DNA replication in cancer cells, the result of which is cell death. Most, if not all, topo-I inhibitors are derivatives of the plant extract camptothecin. Topotecan is a derivative of camptothecin which has been structurally modified to increase water solubility. The pharmacokinetic profile of topotecan is usually characterised by a two-compartment model and is linear in the dose range of 0.5 - 3.5 mg/m(2). Current clinical trials suggest antitumour activity against a variety of human tumour types, including ovarian cancer, non-small cell lung cancer (NSCLC) and non-lymphocytic haematologic malignancies. The main dose-limiting toxicity (DLT) is non-cumulative myelosuppression. Non-haematologic toxicities are usually mild. Based on several Phase I studies, the recommended Phase II dose was 1.5 mg/m(2)/day iv. for 5 days. Current Phase I and Phase II trials are evaluating the combination of topotecan with other chemotherapeutic agents to increase the therapeutic benefits of topotecan. The DLT in these trials is mainly myelosuppression.

References

Apr 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E K RowinskyS H Kaufmann
Sep 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·S V AmbudkarI Pastan
Jan 1, 1995·Cancer Chemotherapy and Pharmacology·L J van WarmerdamJ H Beijnen
Jan 1, 1994·Investigational New Drugs·T M LawR J Motzer
Sep 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C F StewartC B Pratt
Mar 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C B PrattJ T Sandlund
Mar 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H HochsterR Z Vinci
Jan 1, 1994·Cancer Treatment Reviews·G J CreemersJ Verweij
Mar 29, 1996·The Journal of Biological Chemistry·L StewartJ J Champoux
Feb 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R Perez-SolerW K Hong
Apr 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E K RowinskyR C Donehower
Aug 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J H SchillerD Johnson
Jan 1, 1995·Investigational New Drugs·G R HudesB J Giantonio
Sep 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G J CreemersJ Verweij
Jan 1, 1996·Investigational New Drugs·R M ScherP J O'Dwyer
Dec 1, 1996·Molecular and Cellular Biology·S G MorhamO Smithies
Dec 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G J CreemersW W Ten Bokkel Huinink
Dec 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S O'ReillyL B Grochow
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J R MurrenY C Cheng
Mar 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G J CreemersD D Von Hoff
Sep 26, 1997·The Journal of Biological Chemistry·S D DesaiP D'Arpa
Nov 14, 1997·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M L Rothenberg
Dec 10, 1997·American Journal of Clinical Oncology·L B SaltzD P Kelsen
Mar 10, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·V M HerbenW W ten Bokkel Huinink
Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J von PawelR Gralla
Jun 11, 1999·American Journal of Clinical Oncology·E G LevineI C Henderson
May 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M J de JongeJ Verweij

❮ Previous
Next ❯

Citations

Oct 21, 2003·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·F Anthony Greco
Nov 27, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M BoucaudF Bressolle
Jan 29, 2016·Toxicology in Vitro : an International Journal Published in Association with BIBRA·Yanling ChenMenghang Xia
Aug 19, 2005·Expert Review of Anti-infective Therapy·Jean Hou, Eugene Major
May 3, 2008·Cancer Research·Christin TseSteven W Elmore
Aug 22, 2020·Experimental Cell Research·Xiuxiu LiuStefano Gastaldello

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Related Papers

JAMA : the Journal of the American Medical Association
W R BauerK P Johnson
Transplant Infectious Disease : an Official Journal of the Transplantation Society
A M Kazory, D Ducloux
Lung Cancer : Journal of the International Association for the Study of Lung Cancer
A A Miller, H B Niell
© 2021 Meta ULC. All rights reserved